Skip to content

Effects of benzylpiperazine derivatives on the acute effects of 3,4-methylenedioxymethamphetamine in rat brain.

Kenji Hashimoto

Neuroscience Letters April 1, 1993 DOI: 10.1016/0304-3940(93)90472-w (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Animal pharmacology experiment Peer reviewed
Population Rat brain tissue (synaptosomes) and rats
Interventions 3 4-methylenedioxymethamphetamine (MDMA) p-nitrobenzylpiperazine p-chlorobenzylpiperazine 1-piperonylpiperazine desipramine imipramine
Duration 3 hours after MDMA administration
Topics Serotonin MDMA
Keywords Synaptosomes Animals Rats, wistar N-methyl-3,4-methylenedioxyamphetamine Hydroxyindoleacetic acid Piperazines Desipramine Imipramine Brain chemistry Male
Key findings Coadministering benzylpiperazine derivatives significantly attenuated MDMA-induced serotonin reduction in rat brain, while the stronger serotonin uptake inhibitors desipramine and imipramine did not. The authors suggest these benzylpiperazines may inhibit MDMA's acute effects via a mechanism other than serotonin uptake inhibition.

Abstract

The reduction of 5-hydroxytryptamine (5-HT) in rat brain 3 h after administration of 3,4-methylenedioxymethamphetamine (MDMA) was attenuated significantly by coadministration of benzylpiperazine derivatives (p-nitrobenzylpiperazine, p-chlorobenzylpiperazine and 1-piperonylpiperazine), which were weak inhibitors of [3H]5-HT uptake into rat brain synaptosomes. However, the coadministration of desipramine and imipramine which were more potent 5-HT uptake inhibitors than these benzylpiperazines, did not attenuate the reduction of 5-HT by MDMA. These results suggest that these benzylpiperazines might inhibit the acute effects of MDMA by a novel neuropharmacological effect other than 5-HT uptake inhibition.

Comparable studies

Other preclinical and animal studies on MDMA, most cited first.

Citations in the library

Explore topics